KBC Group
SLS icon

KBC Group’s SELLAS Life Sciences SLS Stock Holding History

KBC Group’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Buy
+5,854
New +$40.4K ﹤0.01% 1496

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

KBC Group's SLS Position: Q2 2026 in Review

KBC Group opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 5,854 shares worth $86K. The stake represents ﹤0.01% of the portfolio and ranks #1496 among its holdings.

192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • KBC Group held 5,854 shares of SELLAS Life Sciences worth $86K as of Q2 2026.
  • SELLAS Life Sciences was a new KBC Group position in Q2 2026.
  • SELLAS Life Sciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1496 holding.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.